All these accumulating data make FXR a promising pharmaceutical target for multiple diseases, especially those related to metabolic disorders such as diabetes and cholestasis (Schaap et al., 2014; Gonzalez et al., 2016; Yuan and Li, 2016; Filho et al., 2017). The gene discussed is NR1H4; the disease is cholestasis.